Please assess the completion status of the following clinical trial:

Trial Title: Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has a diagnosis of AD or Mild Cognitive Impairment (MCI) due to AD.~* The patient has evidence of an abnormal amyloid and tau status, consistent with AD, by means of a positive CSF test at screening~* The patient is aged ≥50 and ≤85 years. If a woman, the patient must be post-menopausal.~Exclusion Criteria:~* The patient has participated in a clinical study where he/she has received passive or active anti-Aβ immunotherapy or other active immunisation for the treatment of AD.~* The patient has, in the investigator's opinion, evidence and/or history (clinically or on MRI) of any clinically significant neurodegenerative disease, serious neurological disorder, other intracranial or systemic diseases or conditions resulting in a definite or probable diagnosis of Major or Mild Neuro-Cognitive disorder other than AD, per DSM-5® criteria.~Other in- and exclusion criteria may apply

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 - dose regimen 1 (Type: EXPERIMENTAL): Cohort 1: encompasses patients enrolled prior to the PA1
- Cohort 2 - dose regimen 2 (Type: EXPERIMENTAL): Cohort 2: 10 patients who will receive one administration of booster vaccine prior to the first IMP administration
- Cohort 2 - dose regimen 3 (Type: EXPERIMENTAL): Cohort 2: 10 patients who will not receive a booster vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).